U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

[Business Wire] – AstraZeneca today announced that the U.S. Food and Drug Administration has approved the Bydureon® Pen 2 mg as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. more

View todays social media effects on AZN

View the latest stocks trending across Twitter. Click to view dashboard

See who Astrazeneca is hiring next, click here to view